Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +336.03%
#4 aPriori aPriori +129.63%
#5 Bedrock Bedrock +71.69%
#6 Cysic Cysic +50.00%
#7 Prom Prom +41.40%
#8 Playnance Playnance +35.14%
#9 COTI COTI +31.27%
#10 Bitway Bitway +27.79%
Coin of the day
Wrapped One Wrapped One
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

SOBI
शेयरों में रैंक #1377
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in... Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
शेयर मूल्य
$49.68
मार्केट कैप
$17.25B
बदलाव (1 दिन)
0.77%
बदलाव (1 वर्ष)
72.50%
देश
SE
व्यापार Swedish Orphan Biovitrum AB (SOBI)

श्रेणी

Healthcare
Swedish Orphan Biovitrum AB (SOBI) के लिए कमाई
2026 में कमाई TTM: 0
Swedish Orphan Biovitrum AB की नवीनतम वित्तीय रिपोर्टों के अनुसार, कंपनी की वर्तमान कमाई 0 है। 2026 में कंपनी ने 0 की कमाई की, जो 2026 की कमाई 0 के के बराबर है। इस पृष्ठ पर दिखाई गई कमाई ब्याज और कर से पहले की कमाई है, जिसे EBIT कहा जाता है।
Swedish Orphan Biovitrum AB के लिए कमाई का इतिहास 2026 से 2026 तक
प्रत्येक वर्ष के अंत में कमाई
वर्ष कमाई परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।
समान कंपनियों या प्रतियोगियों की कमाई
कंपनी कमाई कमाई में अंतर देश
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
$1.35B -
US
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
- -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
- -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
$26.37M -
US
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
$992.42M -
HK